Myriad Genetics, Inc.

Myriad International Gmbh

Julia Reid

Alexander Gutin

Steven Stone

Susanne Wagner

Kirsten Timms

Victor Abkevich

Marsel Scheer

Ralf Kronenwett

Fabiana Filigheddu

Steve Stone

This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

Methods and materials for assessing homologous recombination deficiency

Provided herein are methods for predicting chemotherapy benefit. The invention predicts chemotherapy benefit based on the expression analysis of biomarkers, e.g., RNA biomarker transcription analysis, taken from a tumor sample. The biomarker expression data can be combined with clinical variables, e.g., tumor size and nodal status, to generate a profile that predicts the benefit of including chemotherapy as a treatment decision.

Method of using biomarkers and clinical variables for predicting chemotherapy benefit

Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.

Gene signatures for cancer prognosis

Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.

Cancer Biomarkers

Cancer biomarkers

Biomarkers and methods using the biomarkers for molecular detection and classification of disease and, particularly, molecular markers for cancer diagnosis and prognosis and methods of use thereof are provided.

Gene signatures for cancer diagnosis and prognosis

Methods of using a genetic polymorphic variation in the human beta-1 adrenergic receptor gene as a drug response marker are presented. Determining the presence or absence of the A145G genetic variation in the human beta-1 adrenergic receptor gene is useful in predicting an individual's relative response to different antihypertensive drugs; optimizing antihypertensive treatment for an individual; selecting candidate human subjects for participation in clinical trials involving antihypertensive drugs; and, predicting the relative responses among a plurality of individuals to an antihypertensive drug.

Growing community of inventors

Salt Lake City, UT, United States of America

Julia Reid